Study Overview
This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.
Description
To find the highest tolerable dose of IACS-6274 that can be given alone, in combination with bevacizumab and paclitaxel, or in combination with capivasertib to patients who have solid tumors. The safety and tolerability of the study drug(s) will also be studied.
Official Title
A Phase 1 Open-Label, Dose-Escalation and Dose-Expansion Study to Investigate the Safety, Pharmacokinetics, and Anti-Tumor Activity of IACS-6274 as Monotherapy and in Combination in Patients With Advanced Solid Tumors
Quick Facts
Study Start:2021-09-09
Study Completion:2026-05-29
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
| Inclusion Criteria | Exclusion Criteria |
|---|
| |
Contacts and Locations
Study Locations (Sites)
M D Anderson Cancer Center
Houston, Texas, 77030
United States
Collaborators and Investigators
Sponsor: M.D. Anderson Cancer Center
- Timothy A Yap, MD, PRINCIPAL_INVESTIGATOR, M.D. Anderson Cancer Center
Study Record Dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Registration Dates
Study Start Date2021-09-09
Study Completion Date2026-05-29
Study Record Updates
Study Start Date2021-09-09
Study Completion Date2026-05-29
Terms related to this study
Additional Relevant MeSH Terms
- Advanced Endometrial Carcinoma
- Advanced Head and Neck Squamous Cell Carcinoma
- Advanced Malignant Solid Neoplasm
- Advanced Melanoma
- Advanced Ovarian Clear Cell Adenocarcinoma
- Chondrosarcoma
- Clinical Stage III Cutaneous Melanoma AJCC v8
- Clinical Stage IV Cutaneous Melanoma AJCC v8
- Pathologic Stage III Cutaneous Melanoma AJCC v8
- Pathologic Stage IIIA Cutaneous Melanoma AJCC v8
- Pathologic Stage IIIB Cutaneous Melanoma AJCC v8
- Pathologic Stage IIIC Cutaneous Melanoma AJCC v8
- Pathologic Stage IIID Cutaneous Melanoma AJCC v8
- Pathologic Stage IV Cutaneous Melanoma AJCC v8
- Recurrent Ovarian High Grade Serous Adenocarcinoma
- Refractory Endometrial Carcinoma
- Refractory Head and Neck Squamous Cell Carcinoma
- Refractory Melanoma
- Refractory Ovarian Clear Cell Adenocarcinoma
- Refractory Ovarian High Grade Serous Adenocarcinoma
- Stage III Ovarian Cancer AJCC v8
- Stage III Uterine Corpus Cancer AJCC v8
- Stage IIIA Ovarian Cancer AJCC v8
- Stage IIIA Uterine Corpus Cancer AJCC v8
- Stage IIIA1 Ovarian Cancer AJCC v8
- Stage IIIA2 Ovarian Cancer AJCC v8
- Stage IIIB Ovarian Cancer AJCC v8
- Stage IIIB Uterine Corpus Cancer AJCC v8
- Stage IIIC Ovarian Cancer AJCC v8
- Stage IIIC Uterine Corpus Cancer AJCC v8
- Stage IIIC1 Uterine Corpus Cancer AJCC v8
- Stage IIIC2 Uterine Corpus Cancer AJCC v8
- Stage IV Ovarian Cancer AJCC v8
- Stage IV Uterine Corpus Cancer AJCC v8
- Stage IVA Ovarian Cancer AJCC v8
- Stage IVA Uterine Corpus Cancer AJCC v8
- Stage IVB Ovarian Cancer AJCC v8
- Stage IVB Uterine Corpus Cancer AJCC v8